XCancer

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Description:

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Sponsor:

Unknown Organization

Phase:

Phase 1/2

Contacts:

Steve Kye, MD, MPH (CONTACT)

clinicaltrials@pathos.com

708-232-3791

Government Study Link:

NCT06785636 - Click here to see study on

ClinicalTrials.gov

vipivotide tetraxetan

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
  • Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable1b / 2a
  • Histologic documentation of prostate adenocarcinoma
Exclusion
  • No prior chemotherapy for mCRPC
  • 1 line of prior any ARPI therapy
  • Must have received at least 2 cycles of PLUVICTO®
  • Any liver metastases confirmed by biopsy or evidence of lesions \>1 cm consistent with liver metastases on imaging.